Leslie Carol Botha: It’s a miracle – the HPV vaccines cause a reverse herd immunity! Why get vaccinated when you can be protected by the girl next door? I am really trying to digest this… even the title speaks of absurdity. My gut instinct tells me that study participants were tested at different times of their menstrual cycle – when viruses come and go based on immunity – and they pulled the reduced incidences of HPV prevalence when women’s immunity was high – therefore the virus was not present. As noted by Dr. Hanan Polansky, viruses that are dormant do as much damage or more as active viruses. Oh, yeah and there is the documented fact that viruses have cycles like we do. That is why there are infectious disease outbreaks at predictable times.
Guess I am going to have to research who funded this ‘media marketing’ study.
One more thought… 90% of women pass HPV through their bodies without incident. Hmmm. Still sounds like someone is whitewashing the HPV vaccine failure.
HPV vaccinations lower infection rate even among unvaccinated women
By Rachael Rettner
Published July 09, 2012
Among the women in the study, there was a decrease in the percentage who were infected with the four HPV strains included in the vaccine (HPV 6, 11, 16, and 18) in the years after the vaccine was introduced, compared with earlier years.
This decrease in HPV prevalence was seen among both vaccinated and unvaccinated women, the researchers said.
The findings show that even with relatively low rates of women getting vaccinated, the vaccine produces some degree of herd immunity — protection of unvaccinated people that occurs because a critical portion of the population has been vaccinated.
However, while the findings are encouraging, “This is not reason not to get vaccinated,” said study researcher Dr. Jessica Kahn, a physician of adolescent medicine at Cincinnati Children’s Hospital. Kahn noted that one in four unvaccinated participants in the study were infected with a high-risk strain of HPV. A woman can also protect her partner by getting vaccinated, Kahn said.
Because the study was conducted in just one community of mainly African American women, further research is needed to confirm the results and see if the findings apply to the population as a whole.
The first HPV vaccine, called Gardasil and manufactured by Merck, was licensed for use in the United States in June 2006.
To study the effect of the vaccine, Kahn and colleagues analyzed information from two groups of sexually active women ages 13 to 26. One group consisted of 368 women who were not vaccinated, and who visited clinics in Cincinnati between 2006 and 2007. The second group consisted of 409 women who visited the clinics between 2009 and 2010, about 60 percent of whom had received at least one of the three shots in the HPV-vaccination series.
Overall, the percentage of women infected with one of the HPV strains included in the vaccine decreased from 31 percent in the group that visited the clinics between 2006 and 2007, to 13.4 percent in the group that visited in 2009 and 2010 — a 58 percent decrease